At ASCO 2020 meeting, the new final survival results of the SPARTAN study were reported. When we look at overall survival in SPARTAN, the use of apalutamideprolongs survival from 60 months to 74 months – that is a 14-month survival advantage, with a hazard ratioof 0.78. Earlier reports have shown significant advantages in reduction of metastasis development rates and the time to symptomatic regression.
MEST SETE MEDtalks
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer Se hele webinar
In this MEDtalk, Eric J. Small talks about to which extent patients with non-metastatic castration-resistant prostate cancer achieve metastasis-free survival and whether it is possible to delay the time until chemotherapy, as well as the impact of treatment on survival.